The fish, called AquAdvantage, are genetically altered to grow twice as fast as normal Atlantic salmon. The FDA is weighing whether to approve the fish for the U.S. market and is set to hold a three-day public meeting starting September 19.
In more than 200 documents released ahead of the meeting, FDA staff also said the fish were "highly unlikely" to produce significant effects on the environment, Reuters reported. (Click here to see all of the documents.)
The FDA said it has "a high degree of certainty in it conclusions" regarding the safety of AquAdvantage salmon
"We're very pleased with the progress," AquaBounty CEO Ron Stotish told IntraFish on Friday.
